Novel autologous dendritic cell vaccine therapy targeting HTLV-1 specific antigen Combined with anti-CCR4 antibody for previously treated patients with adult T-cell leukemia. A phase Ia/Ib study.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Mogamulizumab (Primary)
- Indications T cell lymphoma; T-cell leukaemia
- Focus Adverse reactions
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2015 New trial record